As of close of business last night, Zomedica Corp’s stock clocked out at $0.14, down -2.83% from its previous closing price of $0.14. On the day, 2896151 shares were traded.
Ratios:
To gain a deeper understanding of ZOM’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.49 and its Current Ratio is at 11.06. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Dawson James on January 06, 2023, initiated with a Buy rating and assigned the stock a target price of $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 15 ’23 when POWERS JOHNNY D bought 100,000 shares for $0.17 per share. The transaction valued at 16,500 led to the insider holds 1,950 shares of the business.
POWERS JOHNNY D bought 100,000 shares of ZOM for $16,600 on Nov 17 ’23. The Director now owns 1,850,000 shares after completing the transaction at $0.17 per share. On Nov 17 ’23, another insider, HEATON LARRY C II, who serves as the CEO of the company, bought 100,000 shares for $0.17 each. As a result, the insider paid 16,600 and bolstered with 200,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZOM now has a Market Capitalization of 137.88M and an Enterprise Value of 50.11M. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.47 while its Price-to-Book (P/B) ratio in mrq is 0.57. Its current Enterprise Value per Revenue stands at 1.99 whereas that against EBITDA is -1.71.
Stock Price History:
Over the past 52 weeks, ZOM has reached a high of $0.25, while it has fallen to a 52-week low of $0.12. The 50-Day Moving Average of the stock is 0.1347, while the 200-Day Moving Average is calculated to be 0.1702.
Shares Statistics:
It appears that ZOM traded 5.56M shares on average per day over the past three months and 5.09M shares per day over the past ten days. A total of 979.95M shares are outstanding, with a floating share count of 964.36M. Insiders hold about 1.59% of the company’s shares, while institutions hold 8.88% stake in the company. Shares short for ZOM as of Mar 15, 2024 were 57.82M with a Short Ratio of 10.41, compared to 57.05M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.90% and a Short% of Float of 6.00%.
Earnings Estimates
As of right now, 1 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was -$0.01. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between -$0.01 and -$0.01 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0, with 1 analysts recommending between $0 and $0.
Revenue Estimates
In the current quarter, 1 analysts expect revenue to total $8.18M. It ranges from a high estimate of $8.18M to a low estimate of $8.18M. As of the current estimate, Zomedica Corp’s year-ago sales were $5.48M, an estimated increase of 49.20% from the year-ago figure. For the next quarter, 1 analysts are estimating revenue of $8.35M, an increase of 38.70% less than the figure of $49.20% in the same quarter last year. There is a high estimate of $8.35M for the next quarter, whereas the lowest estimate is $8.35M.
A total of 1 analysts have provided revenue estimates for ZOM’s current fiscal year. The highest revenue estimate was $34.1M, while the lowest revenue estimate was $34.1M, resulting in an average revenue estimate of $34.1M. In the same quarter a year ago, actual revenue was $25.19M, up 35.40% from the average estimate. Based on 1 analysts’ estimates, the company’s revenue will be $39.19M in the next fiscal year. The high estimate is $39.19M and the low estimate is $39.19M. The average revenue growth estimate for next year is up 14.90% from the average revenue estimate for this year.
